Phibro Animal Health (NASDAQ:PAHC) Announces Quarterly Earnings Results

Posted by Geri Gentry on Aug 28th, 2026

Phibro Animal Health (NASDAQ:PAHC – Get Free Report) announced its quarterly earnings data on Wednesday. The company reported $0.85 earnings per share for the quarter, beating the consensus estimate of $0.71 by $0.14, FiscalAI reports. The firm had revenue of $396.75 million for the quarter, compared to analyst estimates of $381.18 million. Phibro Animal Health had a net margin of 6.57% and a return on equity of 39.28%. Phibro Animal Health updated its FY 2027 guidance to 3.410-3.590 EPS.

Phibro Animal Health Stock Up 0.7%

Phibro Animal Health stock opened at $36.35 on Friday. The firm has a market capitalization of $1.47 billion, a price-to-earnings ratio of 14.90, a price-to-earnings-growth ratio of 0.51 and a beta of 0.46. The firm’s fifty day moving average price is $34.04 and its two-hundred day moving average price is $42.32. Phibro Animal Health has a 1-year low of $28.25 and a 1-year high of $60.08. The company has a current ratio of 3.17, a quick ratio of 1.26 and a debt-to-equity ratio of 1.97.

Phibro Animal Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 23rd. Shareholders of record on Wednesday, September 2nd will be paid a $0.12 dividend. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.3%. The ex-dividend date of this dividend is Wednesday, September 2nd. Phibro Animal Health’s dividend payout ratio (DPR) is 20.60%.

Institutional Investors Weigh In On Phibro Animal Health

A number of institutional investors and hedge funds have recently made changes to their positions in PAHC. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Phibro Animal Health by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,164 shares of the company’s stock valued at $260,000 after purchasing an additional 546 shares during the last quarter. Millennium Management LLC increased its holdings in Phibro Animal Health by 74.3% during the 1st quarter. Millennium Management LLC now owns 362,030 shares of the company’s stock worth $7,733,000 after purchasing an additional 154,281 shares in the last quarter. Jane Street Group LLC increased its holdings in Phibro Animal Health by 65.3% during the 1st quarter. Jane Street Group LLC now owns 33,917 shares of the company’s stock worth $724,000 after purchasing an additional 13,404 shares in the last quarter. Cetera Investment Advisers raised its stake in shares of Phibro Animal Health by 63.0% in the second quarter. Cetera Investment Advisers now owns 18,830 shares of the company’s stock worth $481,000 after purchasing an additional 7,280 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its stake in shares of Phibro Animal Health by 2.9% in the second quarter. JPMorgan Chase & Co. now owns 13,005 shares of the company’s stock worth $332,000 after purchasing an additional 363 shares during the last quarter. Institutional investors and hedge funds own 99.34% of the company’s stock.

Analysts Set New Price Targets

PAHC has been the subject of several research reports. Zacks Research downgraded Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 21st. Citigroup dropped their price target on Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating on the stock in a research note on Thursday, May 14th. Wall Street Zen lowered Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Finally, Weiss Ratings cut Phibro Animal Health from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, June 15th. One investment analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $42.50.

Read Our Latest Research Report on Phibro Animal Health

Key Stories Impacting Phibro Animal Health

Here are the key news stories impacting Phibro Animal Health this week:

Positive Sentiment: Fourth-quarter earnings and revenue beat estimates: Phibro reported revenue of approximately $396.7 million, up 5% year over year and above the $381.2 million consensus estimate. Reported EPS of $0.85 exceeded expectations of $0.71. Phibro fiscal fourth-quarter results and guidance
Positive Sentiment: Profitability improved: Net income increased to $21.7 million, while third-party data indicated diluted EPS of $0.53, both more than 26% above the prior-year period. Gross profit and operating profit also rose, suggesting stronger margin execution. Phibro earnings performance
Positive Sentiment: Above-consensus fiscal 2027 outlook: Management expects EPS of $3.41 to $3.59, compared with the approximately $3.34 analyst consensus, and net sales of roughly $1.55 billion to $1.60 billion, above prior expectations near $1.5 billion. The outlook assumes only a minimal contribution from Brazil virginiamycin sales, reducing reliance on that opportunity. Phibro fiscal 2027 outlook
Neutral Sentiment: Cash generation remained positive: Operating cash flow was $24.1 million, against $18.9 million of capital expenditures. However, the company carried approximately $1.2 billion in total liabilities, keeping leverage a factor for investors.
Negative Sentiment: Insider selling remains a concern: Third-party data showed substantially more insider selling than buying over the past six months, including significant sales attributed to CEO Jack Bendheim. This may temper sentiment despite the strong earnings report. Phibro insider activity

Phibro Animal Health Company Profile

(Get Free Report)

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.